Merck & Co. stock gains analyst support as HSBC lifts price target
Published on 09/10/2026 at 14:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock (ISIN US58933Y1055) is drawing renewed attention from investors after fresh analyst updates and solid recent earnings figures, with the shares lately trading around USD 147 on the New York Stock Exchange as of September 10, 2026.
Analysts lift price targets for Merck & Co.
Analyst sentiment on Merck & Co. remains supportive, with several houses reiterating positive views and lifting their price targets in early September 2026. According to MarketBeat on September 9, 2026, Leerink Partners raised its price target for Merck & Co. to USD 161 while maintaining an Outperform rating, in the context of a broader consensus that currently sits at an average target of about USD 150.33 per share.
The positive momentum continued on September 10, 2026, when HSBC increased its price target on Merck & Co. from USD 150 to USD 172 and kept a Buy rating on the stock, as reported by TipRanks/The Fly. This move represents a USD 22 increase on HSBC's prior target and places the new objective roughly 16.7 percent above the current consensus level around USD 150.33 per share, underlining the bank's confidence in Merck's medium-term growth prospects.
Recent earnings and pipeline drive the story
Beyond analyst calls, Merck & Co.'s latest quarterly figures provide the fundamental backdrop for the recent optimism. As summarized by MarketBeat on September 10, 2026, Merck & Co. last reported quarterly earnings for the period ended in the second quarter of 2026, posting revenue of USD 16.61 billion against analyst expectations of USD 16.37 billion.
On the earnings line, Merck & Co. delivered an earnings per share figure of negative USD 0.13 in that quarter, beating the consensus estimate of negative USD 0.26 by USD 0.13 per share, according to MarketBeat. That beat illustrates the company's ability to manage near-term pressures while delivering slightly better-than-expected profitability, even in a quarter marked by significant investments and one-time effects.
The revenue trajectory is also constructive. Merck & Co.'s quarterly sales of USD 16.61 billion in Q2 2026 represented an increase of approximately 5.1 percent compared with the same quarter a year earlier, as noted by MarketBeat. For investors, this mid-single-digit revenue growth in the latest quarter, combined with an earnings beat versus consensus, forms one of the key data points supporting the raised price targets.
Looking beyond the quarter, Merck & Co. has set guidance for its fiscal year 2026 earnings per share in a range between USD 2.66 and USD 2.76, according to MarketBeat. Equities research analysts cited in the same overview forecast that Merck & Co. will post around USD 2.76 in earnings per share for the current fiscal year 2026, effectively targeting the upper end of the guidance corridor and signaling confidence that the company can execute on its pipeline and commercial strategy.
Pipeline progress forms another pillar of the bullish case. As discussed in a recent analysis on September 10, 2026, Merck has raised its estimate of potential human-health revenue to more than USD 70 billion by the mid-2030s, backed by investments across oncology, cardiometabolic diseases, ophthalmology, immunology and HIV as well as acquisitions such as Cidara and Terns, according to Yahoo Finance. For shareholders, this long-term pipeline revenue ambition is a central element of the investment story, particularly as Merck prepares for eventual loss of exclusivity on its blockbuster immuno-oncology therapy Keytruda.
Growth and valuation context for the stock
Merck & Co.'s valuation has also been a topic of discussion in recent days. A September 9, 2026, assessment indicated that Merck & Co. was trading at around USD 147.74 per share, compared with an estimated intrinsic value of roughly USD 120.08, implying an overvaluation of about 23 percent at that point, according to GuruFocus. This suggests that while analyst price targets such as HSBC's USD 172 and Leerink's USD 161 embed expectations of continued earnings and pipeline delivery, some valuation models point to a premium versus fundamental fair value.
For investors weighing these signals, the combination of a consensus price target around USD 150.33 per share, individual bullish targets up to USD 172, and a model-based fair value closer to USD 120 highlights a trade-off between growth optimism and valuation discipline. According to MarketBeat on September 10, 2026, Merck & Co. currently carries a consensus rating of Moderate Buy, with sixteen analysts assigning a Buy recommendation and eight rating the stock Hold, underscoring the generally favorable view but also the presence of more cautious voices.
Dividend income remains part of the total-return equation. As noted in the same MarketBeat overview dated September 10, 2026, Merck & Co. recently declared a quarterly dividend of USD 0.85 per share, corresponding to an annualized payout of USD 3.40 and a yield of around 2.3 percent at the prevailing share price, with a dividend payout ratio indicated at roughly 272 percent. While the exact ex-dividend and payment dates in that context refer to the current dividend cycle, the level of cash distribution is a reminder that Merck returns a meaningful portion of its cash flow to shareholders alongside its investment in research and development.
Merck & Co. stock level and trading context
From a market perspective, recent trading data show Merck & Co. shares changing hands near the upper end of their historical range. A September 10, 2026, snapshot indicated that Merck & Co. opened at about USD 147.69 on the New York Stock Exchange, according to MarketBeat, after closing at roughly USD 148.52 on September 9, 2026, per Ad-hoc-news. At that closing level, the stock was virtually unchanged from the prior session, implying a daily move close to 0.0 percent.
For orientation, investors can compare this recent price region around USD 147–148 with the prevailing analyst targets and valuation markers. HSBC's freshly raised target of USD 172 stands roughly 16.5 percent above the USD 147.69 opening price quoted on September 10, 2026, while Leerink Partners' USD 161 target sits about 9 percent over the same reference. In contrast, the GuruFocus fair value estimate of USD 120.08 is approximately 18.8 percent below the current trading band, highlighting the spread between bullish scenarios and more conservative valuation frameworks. This numerical comparison helps investors gauge how much future growth and pipeline success is already reflected in Merck & Co.'s stock price as of early September 2026.
Merck & Co. stock facts
- Company: Merck & Co., Inc.
- ISIN: US58933Y1055
- Ticker: MRK
- Trading venue: NYSE
- Price (as of September 10, 2026): 147.69 USD
- Market capitalization: 364,000,000,000 USD (as of September 9, 2026)
- Sector / Industry: Health Care / Pharmaceuticals
- Index membership: S&P 500
